Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That’s the conclusion I got as well with the placebo rolling right into taking the actual pills. Don’t know why but that sounds familiar, like maybe Missling said that somewhere over the last 6 years.
Then again…..could be wrong
Quick……what’s your response.
That was foolish of BIIB not to do. They’ll eat crow soon enough though.
Their house is on fire, while Anavex is just getting started.
Looks like CRTX may no longer be in the running for ALZ treatment
Yet WSJ insists Medicare is “playing god” by rejecting to pay for that miracle bean of a shot by BIIB except in a trial.
Wouldn’t the drug have to WORK in order to even attempt to say such a thing?
Let alone all the side effects and the additional care the SIDE EFFECTS will incur.
Man, getting paid by BIIB must be great for business.
I always look back and see all the times I could have sold and accumulated more at a lower pps.
It’s never about $$ lost as prices go down, it’s about how much more shares I COULD have had.
https://www.yahoo.com/news/making-sense-of-controversy-over-the-new-alzheimers-drug-225008626.html
Comments section is what’s wrong with peoples thinking.
Say Missling releases stunning never before seen absolutely positive data.
Realistically, you think any positive climb would be sustained in the current environment?
Seems like it would just get us right back to twenty, maybe….
AAA: DO YOU BELIEVE THE FOLLOWING IS IN GENERAL TRUE OR FALSE??????
SAVA is almost $100 down from ITS 2021 high.
ANVS is MORE than $100 down from its 2021 high
Let’s compare apples with apples
Sort of like a P4 before being asked to do it. I like the thinking.
Feb’ish is after today, but before 930 am Feb 23. Which happens to land on the same day Missling will be presenting at a conference with subject of the hour being
“Using Precision Medicine in Clinical Trials to Advancing Therapeutics for both Degenerative & Rare Mitochondrial Diseases”
https://mitochondria-targets.com/program/day-two/
Good read, but for the love of Jesus…..it’s Rett. No s at the end.
Copy > paste > replace Retts with Rett and repost.
Isn’t distributing pills relatively easier than liquid? So if the smaller indications are tight nit, marketing shouldn’t require much work especially if the drug ACTUALLY works.
Heck, Missling said himself they think differently so why not just have Amazon pharmacy be your distributor.
Who’s dying?
I call this a final opportunity as I’m letting friends know the unbelievable upside this stock has from $13s?
Just had to add a few more shares this morning
Good luck to you on your new investment. Remember to keep this ticker in your watch list
Who’s selling this low?
Me thinks data after these investment conferences and surely before the conference Missling will be participating in next month.
A-371 pr did it’s purpose and allowed Missling to discuss its path with a flawless safety profile.
Let the presentations brew for a few days, release the results and we move onward and up.
Anavex has not been following usual since 2015
Who do you think has enough to buy out Anavex?
Just a curious thought as A-371 starts to ramp up making Anavex that much more expensive to buy.
Lucky owner won’t own 1 blockbuster drug, but possibly two, plus all the other patents.
When the CEO of BIIB can say the following at the JP Morgan conference with a straight face…..
“We are witnessing the beginning of a wave of scientific breakthroughs in Alzheimer's and Biogen is very well positioned to lead in this space.”
LOL
Oh they’ll cover it, just in trials. Which makes sense. The question is, is it worth it for BIIB to keep the façade up and go through the trial KNOWING it could be obsolete by the time trial end.
Remember the little guys that benefited you.
Much like the foundations…..
Axovant now going under the ticker SIOX run by Vivek the terrible?
Yea, just another one that bit the dust. Much like the one after, that also changed their name, and soon to be that OTHER co that starts with a S that will happen to change its name AGAIN.
Yet AVXL gets flack for being a photo printing business in its previous life……
And when failure was no longer an option…… they offer alternate conclusions for a failed, dead p3 and clap with exuberance because patients would benefit SO much.
“If Biogen thought Anavex had anything of real value or that Anavex was a competitive threat, they’d have bought the company at a premium long ago in a deal that Anavex’s board and shareholders would not / could not have refused.”
That right there is some fantastic fantasy writing.
What a failure for those suffering from Alzheimer’s.
Seems like he is more focused on getting more tutes on board than getting those commie shorts.
Seems like the better strategy if we DO cross the finish line soon.
That statement may have been correct when we were in the pennies, pre Nasdaq.
Or maybe it could have been said when we went from $18 - sub $2.
However, averaging down to a mere $3 makes that point a nothingburger as we sit over 300% higher where we were just 365 days ago.
How much more beneficial your comments would be if it was said over at the SAVA board.
Poor people that got in at $60,$70,$80,$90+
Christmas rally tomorrow, or we stay under $20 for options expiration?
Much like how No child left behind benefits the child graduating, not so much once they enter the real world
FEB 22-24: 2nd Mitochondria-Targeted Drug Development Summit
Speaker: Christopher Missling
http://mitochondria-targets.com/program/speakers/
2:30pm Using Precision Medicine in Clinical Trials to Advancing Therapeutics for both Degenerative & Rare Mitochondrial Diseases
Synopsis
Assessing clinical data with biomarker-correlated outcomes of ANAVEX2-73 (blarcamesine) in Alzheimer’s, Parkinson’s, and Rett Syndrome
Reviewing mechanistic analysis of involvement of mitochondrial function
https://mitochondria-targets.com/program/day-two/
BIIB - approved and still dropped lower then before it was approved.
SAVA - Drops 20% yesterday to pump 20% today on a nothingburger. Does anything else need to be said about that? No progress, just
AVXL - The rest of the world might very well know them by this time next year
Agree. 56,28,14…$7k. I wouldn’t put myself or loved ones on it at any price.
This should not have been approved PERIOD!
It’s what you do when you have what tutes want, ON THE CHEAP.
Makes those Jan 7 $22 option calls I’m holding a good choice
Great, another therapy that gets heads swollen
You wouldn’t think anything of the second part, but if it shows safe and tolerated….well then we just might possibly own the entire cns market for a while. Possibly being key.
Total worth of the co is anyone’s best guess. Sure wouldn’t be $20/share
One of the main jobs of a CEO is to create value for his/her shareholders.
He may not be doing it at a speed you would like, but hey….that’s why if you disapprove of anything, you sell and move on.
2021 has been a fabulous year for Anavex.
2022 will hopefully be even better.
Not all patient ones agree with a sneak peek either.
I’ll go for 3-71 data and Rett eoy, maybe even revealing what the mystery indication is too
That’s a no brainer. SAVA will probably have been rebranded a few times by then